Questions linger as Novartis, university look to move past Japan Diovan affair
This article was originally published in Scrip
Executive Summary
The Japanese university at the center of a long-simmering controversy over the integrity of data from clinical studies on the cardiovascular protection benefits of Novartis's antihypertensive Diovan (valsartan) is apparently hoping that a prominent public apology following the release of its formal investigation will draw a line under the affair.